TY  - GEN
A1  - Fekete, Stefanie
A1  - Egberts, K.
A1  - Preissler, T.
A1  - Wewetzer, C.
A1  - Mehler-Wex, C.
A1  - Romanos, M.
A1  - Gerlach, M.
T1  - Correction to: Estimation of a preliminary therapeutic reference range for children and adolescents with tic disorders treated with tiapride
T2  - European Journal of Clinical Pharmacology
N2  - Correction to: European Journal of Clinical Pharmacology (2021) 77:163–170 https://doi.org/10.1007/s00228-020-03000-0
KW  - Erratum
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-329467
VL  - 77
IS  - 8
ER  - 
TY  - JOUR
A1  - Fekete, Stefanie
A1  - Egberts, K.
A1  - Preissler, T.
A1  - Wewetzer, C.
A1  - Mehler-Wex, C.
A1  - Romanos, M.
A1  - Gerlach, M.
T1  - Estimation of a preliminary therapeutic reference range for children and adolescents with tic disorders treated with tiapride
JF  - European Journal of Clinical Pharmacology
N2  - Purpose
Tiapride is commonly used in Europe for the treatment of tics. The aim of this study was to examine the relationship between dose and serum concentrations of tiapride and potential influential pharmacokinetic factors in children and adolescents. In addition, a preliminary therapeutic reference range for children and adolescents with tics treated with tiapride was calculated.

Methods
Children and adolescents treated with tiapride at three university hospitals and two departments of child and adolescents psychiatry in Germany and Austria were included in the study. Patient characteristics, doses, serum concentrations, and therapeutic outcome were assessed during clinical routine care using standardised measures.

Results
In the 49 paediatric patients (83.7% male, mean age = 12.5 years), a positive correlation was found between tiapride dose (median 6.9 mg/kg, range 0.97–19.35) and serum concentration with marked inter-individual variability. The variation in dose explained 57% of the inter-patient variability in tiapride serum concentrations; age, gender, and concomitant medication did not contribute to the variability. The symptoms improved in 83.3% of the patients. 27.1% of the patients had mild or moderate ADRs. No patient suffered from severe ADRs.

Conclusions
This study shows that tiapride treatment was effective and safe in most patients with tics. Compared with the therapeutic concentration range established for adults with Chorea Huntington, our data hinted at a lower lower limit (560 ng/ml) and similar upper limit (2000 ng/ml).
KW  - Tourette syndrome
KW  - therapeutic drug monitoring
KW  - serum concentration
KW  - paediatrics
KW  - pharmacokinetics
Y1  - 2021
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-279893
VL  - 77
IS  - 2
ER  - 
TY  - JOUR
A1  - Fekete, Stefanie
A1  - Kulpok, Christine
A1  - Taurines, Regina
A1  - Egberts, Karin
A1  - Geissler, Julia
A1  - Gerlach, Manfred
A1  - Malonga Makosi, Dorothée
A1  - König, Jochem
A1  - Urschitz, Michael S.
A1  - Toni, Irmgard
A1  - Neubert, Antje
A1  - Romanos, Marcel
T1  - Value of a web-based pediatric drug information system to prevent serious adverse drug reactions in child and adolescent psychiatry
JF  - Journal of Neural Transmission
N2  - Psychotropic drugs are frequently prescribed ‘off-label’ to children and adolescents and carry the risk of serious adverse drug reactions (sADR). We examined the frequency of sADRs of psychotropic drugs in pediatric inpatients and explored their potential preventability through following the recommendations of a web-based pediatric drug information system (PDIS). The potential socio-economic impacts of using this online system is also addressed. Routine clinical data from all inpatients treated in a child and adolescent psychiatry department between January 2017 and December 2018 were retrospectively examined for the occurrence of sADRs as defined by the European Medicines Agency. The preventability of the sADRs was assessed based on the information of the PDIS. Furthermore, the expected prolongation of the hospital stay due to sADRs was calculated as well as the associated treatment costs. The study was supported by the Innovation Fund of the Joint Federal Committee, grant number 01NVF16021. In total, 1036 patients were screened of whom 658 (63.5%) received psychopharmacological treatment. In 53 (8.1%) of these patients 54 sADRs were documented, of which 37 sADRs were identified as potentially preventable through PDIS. Mitigating sADR through PDIS would likely have prevented prolonged hospital stays and conferred considerable savings for health insurance companies. PDIS provides systematic and evidence-based information about pediatric psychopharmacotherapy and helps to prevent prescribing errors. Therefore, PDIS is a useful tool to increase drug therapy safety in child and adolescent psychiatry. Further prospective studies are needed to confirm the results.
KW  - adverse effects
KW  - pharmacovigilance
KW  - drug safety
KW  - psychotropic drugs
KW  - mental health
Y1  - 2023
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-324817
VL  - 130
IS  - 1
ER  -